Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.38 |
| ▸ | S100A10 | P60903 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214297 | 1.00 | KMT2A (0.45) | KMT2AMEN1GAAALDH1A1MCHR1 | |
| SCHEMBL4199707 | 0.90 | POLB (0.45) | KMT2AMEN1GAAALDH1A1MCHR1 | |
| SCHEMBL4199704 | 0.90 | POLB (0.45) | KMT2AMEN1GAAALDH1A1MCHR1 | |
| SCHEMBL4202747 | 0.86 | ALDH1A1 (0.42) | KMT2AMEN1GAAALDH1A1MCHR1 | |
| SCHEMBL4207879 | 0.82 | MCHR1 (0.53) | KMT2AMEN1ALDH1A1MCHR1LMNA | |
| SCHEMBL4207886 | 0.82 | MCHR1 (0.53) | KMT2AMEN1ALDH1A1MCHR1LMNA | |
| SCHEMBL4210693 | 0.81 | KCNA5 (0.44) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4210696 | 0.80 | CCR5 (0.38) | UBE2MDCUN1D1 | |
| SCHEMBL4213354 | 0.79 | MCHR1 (0.45) | ALDH1A1MCHR1LMNAUBE2MDCUN1D1 | |
| SCHEMBL4213350 | 0.79 | MCHR1 (0.45) | ALDH1A1MCHR1LMNAUBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488738-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-6998401-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | SUNTORY LIMITED (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050245574-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1045693-B1 | AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-6559146-B1 | Neuroprotective effects by inducing calbindin D28Kd, one of Ca2+-binding proteins | SUNTORY LIMITED (JP) | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245574-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | CAMK2A, CAMK2B, SLC1A2 | KMT2A 2011/4885MEN1 4652/4885GAA 2706/4885 |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | FABP7, SLC1A2, CAMK2A | KMT2A 2239/4885MEN1 4714/4885GAA 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.